Cannabis & cardiovascular: the real risks

In the hour after use, myocardial infarction risk rises 4.8-fold (Mittleman 2001). Cannabis raises heart rate by 20–50 % and can trigger angina in coronary heart disease. Cannabis-associated MIs are reported in people under 50 (Richards 2020). Coronary disease, arrhythmias or hypertension are relative contraindications.

TL;DR

  • THC raises heart rate 20-50 % for 1-2 h; blood pressure rises then drops.
  • Heart-attack risk is ~5× higher in the hour after use – matters mainly with coronary disease.
  • In young healthy adults the absolute risk stays very small.
  • Contraindicated: unstable angina, recent MI, severe heart failure.

Why THC stresses circulation

THC activates sympathetic tone, dilates peripheral vessels and speeds the heart. On already narrowed coronaries the extra oxygen demand can trigger ischaemia.

Who should be extra careful

People > 50 with hypertension, CAD, heart failure, arrhythmias. Combining with stimulants (cocaine, amphetamines) dramatically potentiates risk.

Physiological mechanisms at the cellular level

The body's endocannabinoid system plays an essential role in regulating the cardiovascular system. Cannabinoid type 1 (CB1) receptors are located not only in the brain, but also on the endothelial cells of blood vessels and directly in the myocardial tissue. Activation of these CB1 receptors by exogenous THC leads to a complex cascade that influences vascular tone and triggers a reflex increase in heart rate. This acute strain is usually not a problem for a healthy heart, but can compromise the oxygen supply to the myocardium if the vessels are pre-damaged.

In contrast, CB2 receptors are primarily located on immune system cells and in inflammatory tissue. Research is investigating the extent to which the activation of CB2 receptors could have a modulating effect on inflammatory processes in atherosclerosis. While the acute activation of CB1 receptors by THC is proven to strain the cardiovascular system, experimental approaches to CB2-specific agents potentially show different effects. This differentiated view highlights that the cardiovascular effects of cannabis depend heavily on the specific receptor profile of the cannabinoids consumed.

  • CB1 receptors mediate the acute, cardiovascular-stimulating effects of THC.
  • Vasodilation and reflex tachycardia increase myocardial oxygen demand.
  • CB2 receptors are the focus of research regarding inflammatory vascular processes.
  • The balance between different cannabinoids determines the individual risk profile.

Method of consumption and harm reduction

The method of administration significantly influences cardiovascular strain. Classic smoking of cannabis produces substantial amounts of carbon monoxide through combustion. This gas binds to haemoglobin in the blood, thereby blocking oxygen transport. Consequently, the heart must pump faster and harder to compensate for the lack of oxygen in the tissues. This combination of the pharmacological effect of THC and the physical strain of carbon monoxide drastically increases the risk of ischaemia in patients with coronary heart disease.

Although harm-reduction methods of consumption such as vaporising eliminate combustion products and carbon monoxide, the pure effect of THC on the heart rate remains. With oral ingestion, for example through extracts or edibles, exposure of the respiratory tract is completely eliminated. However, the delayed onset of action carries the risk of accidental overdose. An excessively high dose of orally ingested THC can lead to prolonged circulatory problems, a pronounced drop in blood pressure when standing, and persistent tachycardia, which makes monitoring more difficult.

  • Combustion smoke delivers carbon monoxide, which blocks oxygen transport in the blood.
  • Vaporising protects the lungs, but does not prevent THC-induced tachycardia.
  • Oral ingestion carries risks of overdose due to the delayed onset of action.
  • Moderate consumption and avoiding mixed consumption reduce acute circulatory crises.

Swiss context: Medical cannabis, pilot trials and emergency medicine

In Switzerland, the medical use of cannabis has been newly regulated by law since August 2022. Doctors can now prescribe corresponding medicinal products directly and without an exceptional licence from the FOPH. In patients with pre-existing cardiovascular conditions, this prescribing practice requires a particularly careful risk-benefit assessment. Since medical cannabis often features standardised THC and CBD ratios, the dosage can be controlled more precisely than on the illicit market, which significantly minimises the risk of unforeseen circulatory reactions within the therapeutic framework.

In parallel, the ongoing Swiss pilot trials on the regulated supply of cannabis provide important insights into consumption patterns and the health impacts on the population. Consumers in cities such as Zurich or Basel gain access to quality-tested products, which reduces the risk of contamination. Should acute cardiovascular symptoms such as racing heart or extreme fluctuations in blood pressure nevertheless occur, Tox Info Suisse provides medical advice around the clock on the emergency number 145. In the event of severe symptoms such as chest pain, the regular emergency services must be contacted immediately.

  • Facilitated prescription of medical cannabis since August 2022 requires cardiological caution.
  • Swiss pilot trials enable the monitoring of consumption under controlled conditions.
  • Quality control in legal projects protects against dangerous synthetic cannabinoid mixtures.
  • Tox Info Suisse (telephone 145) serves as the first point of contact for acute overdose symptoms.

FAQ

Is CBD hard on the heart too?

No – CBD is fairly neutral or mildly hypotensive.

Can cannabis trigger atrial fibrillation?

Case reports and registry data suggest yes, especially in predisposed patients.

What is the risk when combining cannabis with coffee or energy drinks?

The combination of THC with caffeinated beverages such as coffee or energy drinks can potentiate cardiovascular strain. Both substances stimulate the sympathetic nervous system through different pathways. While caffeine increases heart rate and blood pressure, THC also leads to an increase in pulse rate. Together, they can lead to unpredictable blood pressure spikes, pronounced tachycardia, or cardiac arrhythmias. Individuals with known heart conditions should strictly avoid such combinations to avoid unnecessarily increasing the risk of acute cardiological events.

Is there a difference between synthetic cannabinoids and natural THC regarding heart health?

Yes, synthetic cannabinoids carry a disproportionately higher risk for the cardiovascular system than natural THC. These artificial substances often act as highly potent, full agonists at the CB1 receptors, whereas natural THC is only a partial agonist. This can lead to extreme overstimulation of the circulatory system. In medical practice and emergency situations, severe cardiac arrhythmias, life-threatening hypertensive crises, and even heart attacks are more frequently observed following the consumption of synthetic cannabinoids, which is why there is an urgent warning against their use.

What role does the age of consumers play in the cardiovascular risks of cannabis?

Age is a decisive risk factor. While young, healthy people usually tolerate the acute increase in heart rate caused by THC without symptoms, the risk increases significantly with age. From middle age onwards, the likelihood of undetected vascular constriction or early-stage hypertension increases. In older consumers, the increased oxygen demand of the heart caused by THC, combined with a simultaneously reduced supply, can more rapidly lead to reduced blood flow to the myocardium, increasing the risk of angina pectoris and heart attacks.